Skip to content

Ketamine Produces Antidepressant Effects by Inhibiting Histone Deacetylases and Upregulating Hippocampal Brain-Derived Neurotrophic Factor Levels in a Diisopropyl Fluorophosphate-Based Rat Model of Gulf War Illness.

Ana Ribeiro-Davis, Dalia Y Al Saeedy, Fay M Jahr, Elisa Hawkins, Joseph L McClay, Laxmikant S Deshpande

The Journal of pharmacology and experimental therapeutics January 17, 2024 DOI: 10.1124/jpet.123.001824 via PubMed

Summary

AI-generated from the abstract

In a rat model of Gulf War Illness (GWI), a single antidepressant dose of ketamine reversed epigenetic changes in the hippocampus. Ketamine inhibited the upregulation of histone deacetylase enzymes, restored acetylation at the Bdnf gene promoter, and increased brain-derived neurotrophic factor (BDNF) protein expression. It also increased dendritic spine density and altered spine types, shifting from S-type to T-type spines. These results suggest ketamine's antidepressant effect in GWI-related depression involves histone modifications that boost BDNF and reshape synaptic connections, supporting further clinical trials for GWI-related depression.

Study at a glance

Characteristics Animal experiment Peer reviewed
Population Male Sprague-Dawley rats exposed to diisopropyl fluorophosphate (DFP) to model Gulf War Illness
Intervention Ketamine
Dose 10 mg/kg
Duration 6 months following DFP exposure; brains dissected 24 hours after ketamine injection
Keywords Ketamine therapy Neuroscience research Veterans health Depression treatment Brain chemistry
Citations 10
Key finding Ketamine inhibits histone deacetylase expression, increases BDNF via histone acetylation at the Bdnf promoter, and alters dendritic spine density and morphology in a rat model of Gulf War Illness-related depression.

Abstract

Approximately one-third of Gulf War veterans suffer from Gulf War Illness (GWI), which encompasses mood disorders and depressive symptoms. Deployment-related exposure to organophosphate compounds has been associated with GWI development. Epigenetic modifications have been reported in GWI veterans. We previously showed that epigenetic histone dysregulations were associated with decreased brain-derived neurotrophic factor (BDNF) expression in a GWI rat model. GWI has no effective therapies. Ketamine (KET) has recently been approved by the Food and Drug Administration for therapy-resistant depression. Interestingly, BDNF upregulation underlies KET's antidepressant effect in GWI-related depression. Here, we investigated whether KET's effect on histone mechanisms signals BDNF upregulations in GWI. Male Sprague-Dawley rats were injected once daily with diisopropyl fluorophosphate (DFP; 0.5 mg/kg, s.c., 5 days). At 6 months following DFP exposure, KET (10 mg/kg, i.p.) was injected, and brains were dissected 24 hours later. Western blotting was used for protein expression, and epigenetic studies used chromatin immunoprecipitation methods. Dil staining was conducted for assessing dendritic spines. Our results indicated that an antidepressant dose of KET inhibited the upregulation of histone deacetylase (HDAC) enzymes in DFP rats. Furthermore, KET restored acetylated histone occupancy at the Bdnf promoter IV and induced BDNF protein expression in DFP rats. Finally, KET treatment also increased the spine density and altered the spine diversity with increased T-type and decreased S-type spines in DFP rats. Given these findings, we propose that KET's actions involve the inhibition of HDAC expression, upregulation of BDNF, and dendritic modifications that together ameliorates the pathologic synaptic plasticity and exerts an antidepressant effect in DFP rats. SIGNIFICANCE STATEMENT: This study offers evidence supporting the involvement of epigenetic histone pathways in the antidepressant effects of ketamine (KET) in a rat model of Gulf War Illness (GWI)-like depression. This effect is achieved through the modulation of histone acetylation at the Bdnf promoter, resulting in elevated brain-derived neurotrophic factor expression and subsequent dendritic remodeling in the hippocampus. These findings underscore the rationale for considering KET as a potential candidate for clinical trials aimed at managing GWI-related depression.

Comments

No comments yet.

Log in to comment